Ge medical life science flexfactory (TM) Zhejiang Changxing production platform officially completed

Zhejiang Changxing January 13, 2020 / Meitong news agency / -- on January 11, 2020, GE Medical life science announced that it is a flexfactory built for clover biopharmaceutical Gamma The production platform was officially completed and put into production At present, the platform is equipped with two 2000L production lines, which will help clover biopharmaceutical accelerate its innovation and development Scb-808 pre filled small volume injection, a biological similar drug for the treatment of rheumatoid arthritis and ankylosing spondylitis, has become the first biological medicine in the production platform With the rapid growth of medical demand and the strong support of relevant government policies such as the 13th five year plan for the development of biological industry, China's biomedical industry is ushering in a stage of rapid development In the face of the booming market environment and increasingly fierce market competition, how to reduce production costs, improve production efficiency and speed up the industrialization of innovative drugs while ensuring product quality has become one of the major issues for biomedical enterprises to win the market Yu Lihua, general manager of GE Medical Life Sciences in Greater China, said: "I am very happy to celebrate the launch of flexfactory production platform together with clover biopharmaceuticals As a long-term partner of China's Biopharmaceutical Enterprises, GE Medical life science has always been committed to helping China's biopharmaceutical enterprises improve their production capacity through cutting-edge technology, excellent overall solutions and perfect services, and ultimately to provide more patients with affordable and high-quality biopharmaceuticals " "Biopharmaceutical is an extremely complex system engineering, which requires leading professional technology to develop and manufacture Clover has a rich pipeline of innovative drugs and high-end bioequivalent drugs, among which scb-808, a bioequivalent drug for the treatment of rheumatoid arthritis and ankylosing spondylitis, has entered the phase III clinical trial stage in China " "We are very pleased to be a long-term partner with GE Healthcare Life Sciences," said Dr Liang Peng, founder, chairman and President of clover Today, flexfactory production platform is completed and officially put into production, opening a new chapter in the development of clover enterprise We believe that with flexfactory production platform solutions, we will accelerate the realization of clover's corporate vision to bring more safe, effective, easy-to-use and affordable biological drugs to Chinese patients " This time, GE Medical life science's flexfactory production platform solution for Trifolium biopharmaceuticals includes cGMP compliant process technology, integration and service packages, and training services, providing full support for its rapid development As an important flexfactory flexible factory project of GE Medical Life Sciences in Greater China, the flexfactory production platform, which meets the requirements of nmpa and FDA regulations, is located in Changxing Economic and Technological Development Zone, Huzhou City, Zhejiang Province It is used for the industrial production of similar and innovative drugs of clover biopharmaceuticals, and can expand the scale of production line according to the future production demand Sven frie, general manager of global enterprise overall solutions of GE Healthcare Life Sciences business unit, said: "as the products developed enter the clinical trial stage, the manufacturers need to constantly improve their production capacity and ensure economic benefits while racing against time With flexfactory production platform, GE Medical life sciences is committed to providing global Biopharmaceutical Enterprises with a set of modular overall solutions from cell culture to batch canning, so as to help our customers achieve stable process scale-up production and more efficient treatment for patients " The flexfactory production platform of GE Medical life sciences is based on a large-scale disposable bioreactor serum-free cell culture technology, and adopts a modern biopharmaceutical production platform with integrated control, which can help Biopharmaceutical Enterprises quickly obtain cGMP production capacity Up to now, GE Healthcare life sciences has provided flexfactory production platform for more than 11 Biopharmaceutical Enterprises in Greater China One time process equipment, flexible modular configuration and highly integrated digital control can greatly reduce the production and operation costs of the enterprise in the early stage and accelerate the production and marketing process of products Adorable adorable